Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Merli

Showing results (31-40 of 156) with videos related to

Pageof 16
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 27, 2022
Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of lifeMonica Guberti, Stefano Botti, Andrea Fusco, et al.
Leukemia & Lymphoma|June 14, 2011
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphomaLuigi Marcheselli, Raffaella Marcheselli, Alessia Bari, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2015
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patientsPier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, et al.
The Lancet. Oncology|February 14, 2014
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyAndrew Davies, Francesco Merli, Biljana Mihaljevic, et al.
Annals of Hematology|September 18, 2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Andrea Ferrario, Francesco Merli, Stefano Luminari, et al.
Ejhaem|August 25, 2020
Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS-CoV-2 positivityMicol Quaresima, Virginia Quaresima, Matteo Maria Naldini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2014
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patientsMichel Meignan, Myriam Sasanelli, René Olivier Casasnovas, et al.
Haematologica|December 26, 2015
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II studyMassimo Federico, Stefano Luminari, Cinzia Pellegrini, et al.
The British Journal of Radiology|March 30, 2016
Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patientsPatrizia Ciammella, Andrea Riccardo Filippi, Gabriele Simontacchi, et al.
Cancers|December 11, 2022
Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell LymphomaAlessia Bari, Chiara Gerardi, Eleonora Allocati, et al.
Pageof 16

Showing results (31-40 of 156) with videos related to

Sort By:
Pageof 16
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 27, 2022
Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of lifeMonica Guberti, Stefano Botti, Andrea Fusco, et al.
Leukemia & Lymphoma|June 14, 2011
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphomaLuigi Marcheselli, Raffaella Marcheselli, Alessia Bari, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 5, 2015
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patientsPier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, et al.
The Lancet. Oncology|February 14, 2014
Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyAndrew Davies, Francesco Merli, Biljana Mihaljevic, et al.
Annals of Hematology|September 18, 2010
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL)Andrea Ferrario, Francesco Merli, Stefano Luminari, et al.
Ejhaem|August 25, 2020
Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS-CoV-2 positivityMicol Quaresima, Virginia Quaresima, Matteo Maria Naldini, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 27, 2014
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patientsMichel Meignan, Myriam Sasanelli, René Olivier Casasnovas, et al.
Haematologica|December 26, 2015
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II studyMassimo Federico, Stefano Luminari, Cinzia Pellegrini, et al.
The British Journal of Radiology|March 30, 2016
Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patientsPatrizia Ciammella, Andrea Riccardo Filippi, Gabriele Simontacchi, et al.
Cancers|December 11, 2022
Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell LymphomaAlessia Bari, Chiara Gerardi, Eleonora Allocati, et al.
Pageof 16